Results 121 to 130 of about 2,009,855 (385)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients [PDF]

, 2012
OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Bacchi, Carlos E., Benine, Lucimara C., Ciol, Heloísa, Ojopi, Elida B., Queiroga, Eduardo M., Silva, Luciana H.   +5 more
core   +5 more sources

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Increased Eps15 homology domain 1 and RAB11FIP3 expression regulate breast cancer progression via promoting epithelial growth factor receptor recycling

Tumor Biology, 2017
Recent research indicates that the C-terminal Eps15 homology domain 1 is associated with epithelial growth factor receptor–mediated endocytosis recycling in non-small-cell lung cancer.
Dandan Tong, Ya-Nan Liang, AA Stepanova, Yu Liu, Xiaobo Li, Letian Wang, Fengmin Zhang, NV Vasilyeva   +7 more
doaj   +1 more source

Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma [PDF]

It is now clear that angiogenesis and angiogenesis factors are important in the pathogenesis of haematological malignancies. High pretreatment levels of serum basic fibroblast growth factor have been shown to be associated with poor prognosis in patients
A Bikfalvi, A Vacca, C Basilico, C Tzabar, C Yiangou, D Birnbaum, D Giri, D Ribatti, E Okon, E Rabizadeh, F Dellacono, G Gruber, I Pazgal, J Folkman, K Yamazaki, M Shaklai, M Toi, M Volm, MH Mangi, ML Iruela-Arispe, NL Harris, O Bairey, O Sezer, P Salven, RT Poon, T Menzel, T Ohta, VD Blanckaert, Y Zimra   +28 more
core   +2 more sources

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells [PDF]

, 2013
The relationship between drug resistance, changes in signaling, and emergence of an invasive phenotype is well appreciated, but the underlying mechanisms are not well understood.
Gertler, Frank, Lauffenburger, Douglas A, Meyer, Aaron Samuel, Miller, Miles Aaron   +3 more
core   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer

Contemporary Oncology, 2022
Shinichiro Okauchi, Kunihiko Miyazaki, Hiroaki Satoh   +2 more
doaj   +1 more source

Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks [PDF]

, 2013
Although many anticancer drugs that target receptor tyrosine kinases (RTKs) provide clinical benefit, their long-term use is limited by resistance that is often attributed to increased abundance or activation of another RTK that compensates for the ...
Grenier, Jennifer K., Lauffenburger, Douglas A., MacBeath, Gavin, Root, David E., Sevecka, Mark, Wagner, Joel Patrick, Wolf-Yadlin, Alejandro   +6 more
core   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

THE EFFECTS OF NITROUS OXIDE ON VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS SOLUBLE RECEPTOR 1 (VEGFR1) IN PATIENT UNDERGOING UROLOGICAL SURGERY [PDF]

, 1969
Yasemin Hakimoglu, Murat Can, Sedat Hakimoğlu, Ayca Gorkem Mungan, Şereften Açıkgöz, Nuran Cıkcıkoğlu Yıldırım, Necmettin Aydin Mungan, Işıl Özkoçak Turan   +7 more
openalex   +1 more source